Although controlling the source of the amyloid precursor protein and factoring hematologic response into efficacy measures is important, they are of limited long-term value to patients in the absence of organ improvement.15 For this reason, using NT-proBNP as a surrogate end point for pivotal clinical trials in patients with AL amyloidosis will advance therapeutic treatments that save lives. Here, NPPB is linked to AL amyloidosis.